Vanda Pharmaceuticals Inc. (VNDA) › Total LiabilitiesVanda Pharmaceuticals Inc. (VNDA) — Total LiabilitiesAnnual figures by period end, from SEC filings.2010-12-31: $175.37M2011-12-31: $149.14M2012-12-31: $125.54M2013-12-31: $99.22M2014-12-31: $10.89M2015-12-31: $80.02M2016-12-31: $79.04M2017-12-31: $74.04M2018-12-31: $56.71M2019-12-31: $72.80M2020-12-31: $80.19M2021-12-31: $88.86M2022-12-31: $107.05M2023-12-31: $103.53M2024-12-31: $117.66M2025-12-31: $161.76M$161.76M2010-12-31Total Liabilities (USD)2025-12-31Period endedTotal LiabilitiesChange YoYSource filing2025-12-31$161.76M+37.5%2026-02-12Balance as of period end2024-12-31$117.66M+13.6%2026-02-12Balance as of period end2023-12-31$103.53M-3.3%2025-02-14Balance as of period end2022-12-31$107.05M+20.5%2024-02-08Balance as of period end2021-12-31$88.86M+10.8%2023-02-09Balance as of period end2020-12-31$80.19M+10.1%2022-02-24Balance as of period end2019-12-31$72.80M+28.4%2021-02-11Balance as of period end2018-12-31$56.71M-23.4%2020-02-26Balance as of period end2017-12-31$74.04M-6.3%2019-02-19Balance as of period end2016-12-31$79.04M-1.2%2018-02-15Balance as of period end2015-12-31$80.02M+635.0%2017-02-17Balance as of period end2014-12-31$10.89M-89.0%2016-02-12Balance as of period end2013-12-31$99.22M-21.0%2015-03-13Balance as of period end2012-12-31$125.54M-15.8%2014-02-25Balance as of period end2011-12-31$149.14M-15.0%2013-02-26Balance as of period end2010-12-31$175.37M—2012-03-09Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)